Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript Summary
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.The following is a summary of the Tivic Health Systems, Inc. (TIVC) Q2 2024 Earnings Call Transcript:
以下是Tivic Health Systems, Inc.（TIVC）2024年第二季度業績會交流摘要：
Financial Performance:
金融業績：
Tivic Health reported lower ClearUP revenues for Q2 2024, totaling $140,000, a 12% decrease year-over-year, primarily due to a 27% decrease in unit sales offset by a 20% increase in the per-unit average sale price.
Gross profits for the three and six months ended June 30 were $30,000 and $197,000 respectively, showing an improvement in gross margin from 32% to 42%.
Net loss for Q2 2024 was $1.3 million, improving from a $2.1 million loss in 2023.
The company achieved a cash position of $3.7 million as of June 30, 2024, compared to $3.4 million at the end of 2023.
Tivic Health報告了2024年第二季度ClearUP收入下降的情況，總額爲140,000美元，同比下降12％，主要是因爲銷售數量下降27％，而每單位平均銷售價格上漲20％。
截至6月30日的三個月和六個月的毛利潤分別爲30,000和197,000美元，毛利率從32％提高到了42％。
2024年第二季度淨虧損爲130萬美元，較2023年虧損210萬美元有所改善。
截至2024年6月30日，該公司的現金餘額爲370萬美元，而2023年底爲340萬美元。
Business Progress:
業務進展：
Tivic Health has made significant progress in the development of a noninvasive vagus nerve stimulation (VNS) system, in collaboration with the Feinstein Institutes for Bioelectronic Medicine.
The company completed Phase 1 trials showing profound biological effects, promising for the treatment of neurological, cardiovascular, and autonomic system diseases.
Tivic Health在與Feinstein Institutes for Bioelectronic Medicine合作的非侵入性迷走神經刺激（VNS）系統的開發方面取得了重大進展。
該公司完成了第一階段試驗，表現出深刻的生物效應，有望治療神經系統、心血管系統和自主神經系統疾病。
Opportunities:
機會：
The new noninvasive VNS system represents a high-value medical target with potential to generate stronger shareholder returns.
Tivic's noninvasive bioelectronic platforms offer significant market differentiation and potential premium pricing, responding to unmet needs in medical-grade noninvasive VNS devices.
The company is exploring alternative monetization strategies for the ClearUP product.
新的非侵入性VNS系統代表着一個高價值的醫療目標，有可能帶來更強的股東回報。
Tivic的非侵入式生物電平台爲醫用非侵入式VNS設備的未滿足需求提供了明顯的市場差異化和潛在溢價定價。
該公司正在探索ClearUP產品的替代變現策略。
Risks:
風險：
Tivic faces risks from operational cutbacks possibly impacting their ability to support new scientific advancements.
Threat of non-compliance with NASDAQ's $1.00 per share minimum bid price requirement, though they have until December 26 to regain compliance.
Tivic面臨着運營裁員可能影響其支持新科學進展能力的風險。
儘管該公司有時間到12月26日恢復遵守納斯達克的每股最低買入價格要求，但面臨不遵守的威脅。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。